Skip to main content

Advertisement

Table 3 HR and 95% CI for the associations between risk factors and 10-year all-cause mortality by tumor molecular subtype

From: Breast cancer risk factors, survival and recurrence, and tumor molecular subtype: analysis of 3012 women from an indigenous Asian population

Risk factor1a 10-year all-cause mortality P hetd
A-like B-like HER2-enriched Triple-negative
N/events HR (95% CI) N/events HR (95% CI) N/events HR (95% CI) N/events HR (95% CI)
Ethnicity  
 Chinese 567/39 1.00 (reference) 435/41 1.00 (reference) 180/38 1.00 (reference) 275/57 1.00 (reference) 0.81
 Malay 204/17 1.23 (0.65, 2.34) 263/70 2.32 (1.49, 3.60) 104/29 1.11 (0.63, 1.96) 155/54 1.22 (0.79, 1.89)  
 Native 245/19 1.04 (0.52, 2.05) 291/39 1.68 (1.02, 2.77) 103/20 0.93 (0.48, 1.79) 190/41 1.06 (0.67, 1.67)  
P value   0.80   0.03   0.87   0.77  
Menarche
  ≤ 12 yrs 344/14 1.00 (reference) 326/52 1.00 (reference) 118/23 1.00 (reference) 190/46 1.00 (reference) 0.06
 13 yrs 318/26 1.53 (0.76, 3.11) 340/44 0.88 (0.55, 1.40) 148/29 0.84 (0.45, 1.57) 201/46 1.21 (0.76, 1.92)  
 14 yrs 163/11 1.25 (0.54, 2.91) 167/27 0.86 (0.50, 1.48) 60/22 0.92 (0.47, 1.80) 111/26 1.05 (0.61, 1.80)  
  ≥ 15 yrs 184/23 2.25 (1.06, 4.78) 148/27 0.84 (0.49, 1.42) 57/11 0.49 (0.21, 1.11) 113/31 0.89 (0.52, 1.55)  
P value   0.06   0.49   0.15   0.66  
Parity and BFb
 Nulliparous 242/24 1.00 (reference) 224/36 1.00 (reference) 77/18 1.00 (reference) 128/40 1.00 (reference) 0.28
 Parous and No BF 133/10 0.59 (0.27, 1.32) 103/12 0.81 (0.37, 1.75) 31/8 0.87 (0.34, 2.25) 64/20 1.02 (0.52, 1.96)  
 Parous and BF 641/41 0.46 (0.26, 0.81) 662/102 0.99 (0.64, 1.56) 279/61 0.61 (0.33, 1.14) 428/92 0.86 (0.55, 1.34)  
P value   0.009   0.91   0.11   0.48  
Age at FFPc
  < 21 yrs 116/10 1.00 (reference) 158/32 1.00 (reference) 54/13 1.00 (reference) 95/19 1.00 (reference) 0.22
 21–24.9 yrs 284/14 0.99 (0.38, 2.55) 287/33 1.30 (0.75, 2.25) 129/28 0.83 (0.37, 1.84) 199/42 0.71 (0.39, 1.29)  
 25–30 yrs 275/23 0.85 (0.41, 1.73) 248/39 1.14 (0.69, 1.90) 103/22 0.77 (0.40, 1.49) 154/41 0.98 (0.60, 1.60)  
  > 30 yrs 99/4 0.36 (0.10, 1.29) 72/10 1.34 (0.64, 2.81) 24/6 0.78 (0.25, 2.46) 43/9 0.53 (0.23, 1.24)  
P value   0.08   0.92   0.15   0.58  
Family history
 No 840/56 1.00 (reference) 854/131 1.00 (reference) 338/73 1.00 (reference) 516/122 1.00 (reference) 0.25
 Yes 160/17 1.70 (0.93, 3.08) 119/17 1.05 (0.59, 1.88) 46/13 1.47 (0.76, 2.82) 92/22 0.77 (0.46, 1.27)  
P value   0.08   0.86      
BMI, kg/m2
 18.5–24.9 160/6 1.00 (reference) 172/25 1.00 (reference) 68/15 1.00 (reference) 114/25 1.00 (reference) 0.80
  < 18.5 373/38 3.42 (1.20, 9.71) 336/43 1.06 (0.62, 1.82) 163/37 0.83 (0.44, 1.57) 240/63 1.15 (0.70, 1.91)  
P value   0.02   0.83   0.58   0.56  
 25–30 317/21 2.88 (0.97, 8.59) 301/49 1.30 (0.77, 2.20) 104/19 0.80 (0.39, 1.64) 177/40 0.92 (0.54, 1.57)  
P value   0.06   0.32   0.54   0.77  
  > 30 136/7 1.30 (0.37, 4.52) 148/23 1.12 (0.61, 2.05) 38/10 1.23 (0.52, 2.90) 66/18 1.21 (0.63, 2.32)  
P value   0.68   0.71   0.63   0.57  
  1. In bold are variables which met our criteria (P value < 0.1) for inclusion in multivariate models
  2. aEach risk factor was adjusted for age, ethnicity, BMI, tumor stage, histologic grade, surgery, systemic therapy (endocrine (tamoxifen or AI versus none), chemotherapy (any regimen versus none)) and radiotherapy (received versus none)
  3. bBF breastfeeding
  4. cFFP first full-term pregnancy
  5. dP value for heterogeneity (P-het) of HR estimates according to molecular subtypes